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The Mental Health Centers for Intervention Development 
and Applied Research (CIDAR) program prioritized research 
to provide an evidence base for biomarker development. At 
the Zucker Hillside Hospital (ZHH), our CIDAR grant sup-
ported research on a comprehensive investigation of treatment 
response and outcome in first episode schizophrenia. Results 
provide evidence that baseline neuroimaging, neurocognitive, 
and genetic measures are significantly associated with clini-
cal response to treatment, and that our currently available 
interventions can effectively treat aspects of psychotic illness, 
as well as potentially reduce comorbidity associated with ill-
ness. Future research may include combining modalities to 
more robustly predict response and identify treatment tar-
gets, as well as to further develop more effective intervention 
strategies for these devastating and disabling disorders.
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In many areas of medicine, heterogeneity of patient out-
comes is managed by the availability of multiple thera-
peutic options, and treatment decisions are guided by 
clinical biomarkers. Well-known examples in broad 
clinical use include the HER2 marker for herceptin treat-
ment of breast cancer,1 and natriuretic peptide levels for 
diagnosis and prognosis of heart failure.2 By contrast, 
treatment options for patients with schizophrenia are 
relatively undifferentiated, and clinicians lack objec-
tive tools to dissect patient heterogeneity with respect to 
treatment and prognosis. Development of biomarkers in 
psychiatry can be critical to both the application of exist-
ing treatments and the development of novel treatments.
The announcement of the Mental Health Centers 
for Intervention Development and Applied Research 
(CIDAR) program in 2005 prioritized research to pro-
vide an evidence base for biomarker development. This 
announcement coincided with an important evolution in 
research at our institution, the Zucker Hillside Hospital 
(ZHH). Developments in neuroimaging, neurocognition, 
and molecular genetics provided the means to broaden 
our treatment research in first episode schizophrenia to 
encompass the development of individualized assessment 
tools to dissect the heterogeneity of treatment response 
in this important population. The CIDAR program pro-
vided the first NIH-funded mechanism to integrate these 
efforts into a comprehensive investigation of treatment 
response and outcome in first episode schizophrenia.
This theme is focused on the first episode of psychosis, 
which may be the most critical period in the life of an indi-
vidual with schizophrenia, and remains the most oppor-
tune time for the study of key mechanisms that influence 
treatment response and outcome of this often chronically 
disabling disorder. Several factors render the first episode 
a critical research window: first episode patients are gener-
ally young, and therefore within a relatively restricted age 
range; they have a shorter duration of psychotic symptoms; 
and less illness-related functional and social impairment 
related to chronicity of illness. Perhaps most critical is that 
first episode patients have minimal prior psychopharma-
cological treatment, reducing medication confounds for 
research aimed at identifying the neurobiological substrates 
associated with illness and the prediction of illness course.
The ZHH CIDAR (P50MH080173; Dissecting the 
heterogeneity of treatment response in first episode schizo-
phrenia; PI: Anil K.  Malhotra), funded in 2008, inte-
grated therapeutic knowledge and experience with the 
expertise of investigators utilizing neurocognitive, neu-
roimaging and molecular genetics approaches to bio-
markers development. We focused on the assessment of 
a cohort of first episode schizophrenia patients partici-
pating in a 12-week clinical trial of 2 second generation 
antipsychotics (SGAs), aripiprazole and risperidone, and 
a follow-up extension phase of controlled treatment for 
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1 year. The primary CIDAR assessments were conducted 
prior to the initiation of treatment and during 12 weeks 
of double-blind treatment. The CIDAR comprises 3 
cores supporting 3 independent projects, with additional 
NIH and FDA funding to support a supplemental proj-
ect focused on the reactions of young people with early 
phase schizophrenia to tobacco smoking warning materi-
als. The major aim of each of the 3 initial projects was to 
identify predictors of SGA response in this cohort, using 
neuroimaging, neurocognitive and genetic indices.
Progress to Date
At the conclusion of CIDAR patient recruitment in 2014, 
198 first episode schizophrenia patients had entered the 
parent clinical trial, with a majority of them contributing 
additional data to the other projects within the CIDAR. 
Initial results include structural neuroimaging studies sug-
gesting that observed antipsychotic-drug induced changes 
in fractional anisotropy, a putative measure of white matter 
integrity, may be related to changes in circulating lipid lev-
els,3 assessments of the relationship of cognitive function to 
brain connectivity,4 and molecular genetics work identify-
ing the melanocortin 4 receptor (MC4R) locus as a strong 
predictor of antipsychotic drug-induced weight gain.5
The CIDAR has been most successful in the adoption 
of resting state MRI (rs-fMRI) to identify biomarkers of 
antipsychotic drug response We have recently published a 
pair of studies demonstrating 2 facets of our approach to 
biomarker development in the context of CIDAR anti-
psychotic drug treatment: (1) identification of baseline 
predictors of treatment response and (2) identification of 
longitudinal indicators of target engagement.6,7
As an example of prognostic biomarker development, we 
utilized seed-based rs-fMRI analysis to examine the relation-
ship between baseline (pretreatment) functional connectivity 
and subsequent response to SGA treatment. A striatal con-
nectivity index (SCI) was established as a predictor of treat-
ment response and replicated in a second sample.6 Sensitivity 
and specificity in the replication sample suggests potential 
clinical application. Post-treatment rs-fMRI scans identi-
fied a different set of striatal connections that changed as a 
function of successful treatment.7 These data are consistent 
with an independent study8 in which symptom improvement 
with antipsychotic treatment was associated with changes in 
fronto-striatal connectivity. These fronto-striatal networks 
may serve as a measure of target engagement in the develop-
ment of novel therapeutic agents.
In This Issue
In this theme issue of Schizophrenia Bulletin, we high-
light results of the pivotal clinical trial at the heart of the 
CIDAR, as well as our most recent findings of prognos-
tic relevance. Robinson and colleagues (this issue) present 
data from the first large scale double-masked first-episode 
randomized comparison of aripiprazole and risperidone. 
One hundred ninety-eight schizophrenia-spectrum partici-
pants (ages 15–40) were randomly assigned and followed 
for 12 weeks. Of note, positive symptom response rates did 
not significantly differ (62.8% vs 56.8%) between treatment 
groups nor was there a significant difference in the mean 
time to achieve clinical response. While positive symptom 
treatment efficacy was similar, there was substantial differ-
ence in side effect profiles. Patients treated with aripiprazole 
experienced greater akathisia during the trial, although dif-
ferences were nonsignificant by the end of trial. By contrast, 
risperidone-treated patients had greater increases in total 
and LDL cholesterol, fasting glucose and prolactin levels. 
Taken together, the data suggest that while both drugs are 
effective in first episode patients, the metabolic advantages 
of aripiprazole may suggest it as a preferred choice over 
risperidone for young patients in whom treatment may be 
indicated for an extended period of time.
The second major aim of the CIDAR: to identify 
pretreatment neurocognitive indices that may be indi-
cators of treatment response is addressed by Trampush 
and colleagues (this issue). Twelve weeks of treatment 
with aripiprazole and risperidone had minimal effects 
on cognitive function, as assessed with the MATRICS 
Consensus Cognitive Battery (MCCB). Although per-
formance on indices of general cognitive function, work-
ing memory, and verbal learning improved over time, 
change was mediated by improvements in both positive 
and negative symptoms, reflecting “pseudospecificity” or 
practice effect.9 These data are consistent with prior work 
from our group in first episode patients,10 as well as stud-
ies in more chronic patients in which minimal effects of 
SGA treatment were found on neurocognitive function.11 
Intriguingly, however, at baseline, a measure of planning 
and reasoning significantly predicted whether positive 
symptom remission was achieved during the 12-week 
trial. These data suggest that a simple paper and pencil 
test may serve as a potentially useful predictive biomarker 
of antipsychotic drug response.
The third paper addresses genetic predictors of anti-
psychotic drug response. Previously, we have found that 
a polymorphism in the promoter region of the DRD2 
gene significantly influenced antipsychotic drug efficacy 
in first episode patients,12 as well as in more chronically 
ill patients.13 Moreover, the PGC consortium reported 
that a locus near the DRD2 gene attained genome-wide 
significance for association to schizophrenia,14 providing 
the first robust evidence that genetic variation in the dopa-
mine system may influence illness susceptibility. Therefore, 
Zhang and colleagues (this issue) assessed the relationship 
of this new DRD2 locus to treatment response and found 
evidence that variation at this risk locus was associated 
with positive symptom treatment response.
The final paper addresses whether tobacco warning 
materials designed to reduce cigarette smoking in the 
general population is effective in young patients with 
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schizophrenia. Schizophrenia is associated with intense 
smoking and related morbitiy and mortality. However, 
warning materials have not been specifically designed for 
use in this population. Coletti and colleagues (this issue) 
examined whether picture and video materials depict-
ing the dangers of smoking, many of which can be quite 
graphic and potentially disturbing, would be acceptable 
to young patients with psychosis. Their data suggest that 
the materials were well-received with some evidence of a 
decline in smoking rates
Taken together, these papers as well as in our previ-
ous rs-fMRI publications, suggest that identification of 
biomarkers of antipsychotic drug response is feasible in 
first episode patient populations and that our currently 
available interventions can effectively treat aspects of 
psychotic illness, as well as potentially reduce comor-
bidity associated with illness. As our CIDAR-supported 
work found evidence that baseline neuroimaging, neuro-
cognitive, and genetic measures are significantly associ-
ated with clinical response to treatment, the next steps 
will include combining modalities to more robustly pre-
dict response and identify treatment targets, as well as to 
further develop more effective intervention strategies that 
help ameliorate the suffering of patients with these devas-
tating and disabling disorders.
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